<DOC>
	<DOCNO>NCT01962324</DOCNO>
	<brief_summary>A single arm phase 2 study study outcome dose-escalation simultaneous integrate boost intraprostatic lesion positive lymph node . Prostate cancer patient high risk lymph node metastasis oligo positive node true pelvic area include . The boost volume outline usin PET-CT MRI data . Our hypothesis few relapse high risk patient group compare match historical control acceptable side effect .</brief_summary>
	<brief_title>Dose Escalation With SIB Intraprostatic/Lymphatic GTV High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lymphatic Metastasis</mesh_term>
	<criteria>Histologically confirm high risk prostate cancer risk lymphatic spread &gt; 15 % accord MSKCC nomogram ( 1 ) http : //nomograms.mskcc.org/Prostate/PreTreatment.aspx Written inform consent &gt; 18 year Fiducial gold marker implant prostate ( min 3 ) â€¢ Non MRsafe implant contraindication MRI WHO PS &gt; 1 Previous pelvic irradiation TURP within 6 month IPSS &gt; 19 Metastatic disease skeleton , parenchymal organ lymph node outside pelvis Creatinin clearance &lt; 30ml/min accord http : //www.fass.se/LIF/produktfakta/kreatinin.jsp</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Quality Life</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Radiotherapy , dose-escalation</keyword>
</DOC>